Several drugs are slated to make their debuts in 2019, but only seven are projected to achieve blockbuster status within four years, according to a new report from analytic firm Cortellis.
A blockbuster drug is defined as one that reaches $1 billion in annual sales.
Below are the projected blockbusters and their projected 2023 sales:
1. Upadacitinib ($2.2 billion). The drug, manufactured by AbbVie, treats rheumatoid arthritis.
2. Zolgensma ($2.09 billion). The drug is manufactured by AveXiz and Novartis to treat spinal muscular atrophy.
3. Roxadustat ($1.97 billion). The drug treats anemia and is manufactured by AstraZeneca, FibroGen and Astellas.
4. Ultomiris ($1.93 billion). The drug treats Paroxysmal nocturnal hemoglobinuria, a rare blood disease that causes red blood cells to break apart. It is manufactured by Alexion.
5. Skyrizi ($1.74 billion). The drug treats psoriasis. It is manufactured by AbbVie and Boehringer Ingelheim.
6. AR101 ($1.17 billion). The biologic drug, manufactured by Aimmune, is designed to protect patients from severe allergic reactions if they are exposed to peanuts.
7. LentiGlobin ($1.12 billion). The drug, manufactured by Bluebird Bio, treats beta thalassemia, a blood disorder that reduces the production of hemoglobin.